Organisation paid for research Program year 2025 Source: CMS Open Payments

Gastroenterology Associates of Western Michigan PLC

Neither a doctor nor a teaching hospital

Research payments

$989,730

327 payments

Through program year 2025, Gastroenterology Associates of Western Michigan PLC is reported as receiving $989,730 in research payments, across 327 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$285,418	94
2024	Research	$166,506	65
2023	Research	$78,403	21
2022	Research	$59,336	21
2021	Research	$110,537	23
2020	Research	$157,402	64
2019	Research	$132,127	39

Breakdown

Who paid Research payments · program years 2019–2025

Teva Pharmaceuticals USA, Inc. $311,080 114 payments
AbbVie, Inc. $250,095 74 payments
Gilead Sciences, Inc. $148,988 39 payments
Bausch Health US, LLC $64,994 32 payments
Pfizer Inc. $48,845 5 payments
Adare Pharmaceuticals, Inc. $43,574 24 payments
Takeda Pharmaceuticals U.S.A., Inc. $42,288 10 payments
F. Hoffmann-La Roche AG $31,475 6 payments
Roche Products Limited $16,244 3 payments
Arena Pharmaceuticals, Inc. $15,877 12 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure $134,629 26 payments
Tv53408-Imm-10197 $128,372 75 payments
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $73,824 12 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $64,994 32 payments
A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $48,845 5 payments
Tv53408-Imm-1097 $48,078 13 payments
CD P3: Double-Blind Induction $42,604 12 payments
M16-006 $37,628 11 payments
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE) $31,196 14 payments
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease $31,098 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.